Evidence map›Paper›PMID 39720423›Full record

ReviewEClinicalMedicine2024

International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set.

Robert Samuel, Stephen R Knight, Richard Adams, Prajnan Das, Jennifer Dorth, David Finch, Marianne G Guren, Maria A Hawkins, Susan Moug, Lakshmi Rajdev and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Robert SamuelNIHR Manchester Biomedical Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.
Stephen R KnightCentre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK.
Richard AdamsCentre for Trials Research, Cardiff University School of Medicine, Cardiff, UK.
Prajnan DasUniversity of Texas MD Anderson Cancer Center, USA.
Jennifer DorthDepartment of Radiation Oncology, University Hospitals Cleveland Medical Centre, Cleveland, USA.
David FinchNIHR Manchester Biomedical Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.
Marianne G GurenDepartment of Oncology, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Maria A HawkinsDepartment of Medical Physics and Biomedical Engineering, University College London, London, UK.
Susan MougDepartment of Colorectal Surgery, Royal Alexandra Hospital, Paisley, UK.
Lakshmi RajdevTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
David Sebag-MontefioreUniversity of Leeds, Leeds Institute for Medical Research, St. James's University Hospital, Leeds, UK.
Andrew G RenehanNIHR Manchester Biomedical Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.
Rebecca FishNIHR Manchester Biomedical Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.
plus the CORMAC-2 collaborators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Variation in outcomes definitions and reporting limit the utility of clinical trial results. The Core Outcome Research Measures in Anal Cancer (CORMAC) project developed a core outcome set (COS) for chemoradiotherapy trials for anal squamous cell carcinoma (ASCC) through an international healthcare professional and patient consensus process. The CORMAC-COS comprises 19 outcomes across 4 domains (disease activity, survival, toxicity, life impact). In CORMAC-2 we have established standardised definitions for the 11 disease activity and survival outcomes in the CORMAC COS. Definitions were agreed through a 3 step process, initially identifying existing definitions through systematic review (registered with PROSPERO, CRD42016036540), using these to populate a two-round Delphi questionnaire completed by 51 experts from 13 countries, and finally ratification through an online consensus meeting. Standardising the definitions for these core outcomes facilitates real world utilisation of the CORMAC-COS, thereby increasing the quality of data available for clinical decision-making and ultimately enhancing patient care.

Indexed as

Anal cancerChemoradiotherapyConsensusCore outcome setDelphiOutcomes

Identifiers

PMID39720423
PMCPMC11667046

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.